InnovAge stock carries a bigger fiscal 2027 growth plan

Published on 10/07/2026 at 02:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

InnovAge stock delivered USD 989.7 million in fiscal 2026 revenue, up 15.9 percent from the prior year. Adjusted EBITDA reached USD 94.6 million.

INNV, US45784A1043, Illustration mit AI erstellt.

InnovAge (ISIN US45784A1043) was last at USD 9.00 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with the quoted daily change at 0 percent. The latest fiscal report showed revenue of USD 989.7 million and adjusted EBITDA of USD 94.6 million, giving the stock a sharper earnings framework for fiscal 2027.

Fiscal 2026 improves profitability

According to Investing.com on September 8, 2026, InnovAge increased fiscal 2026 revenue 15.9 percent to USD 989.7 million from USD 853.7 million in fiscal 2025. Adjusted EBITDA rose to USD 94.6 million from USD 34.5 million, while adjusted EBITDA margin reached 9.6 percent compared with 6.9 percent.

The improvement was not limited to the income statement. TradingView reported that the fiscal 2026 net loss narrowed to USD 2.54 million from USD 30.31 million in fiscal 2025, while diluted loss per share improved to USD 0.02 from USD 0.22. The figures point to operating leverage, but the company still finished the year below break-even on a GAAP basis.

Guidance raises the execution bar

For fiscal 2027, management guided to revenue of USD 1.05 billion to USD 1.085 billion and adjusted EBITDA of USD 105 million to USD 115 million, according to Investing.com. The guidance implies continued revenue growth from the USD 989.7 million fiscal 2026 base and adjusted EBITDA above the prior year's USD 94.6 million.

The company served 8,230 participants across 20 centers as of June 30, 2026, according to InnovAge. California and Colorado represent a material operating consideration because management said their rates had not been finalized in the fiscal 2027 outlook, leaving enrollment, utilization and reimbursement execution central to the forecast.

Consensus target stays above price

MarketBeat lists a Reduce consensus based on four analysts, with an average price target of USD 10.50, a high target of USD 14.00 and a low target of USD 7.00. The average price target lies 16.7 percent above the USD 9.00 Nasdaq price, placing the consensus above the market quote while retaining a wide target spread.

INNV holds a wide yearly range

INNV was last at USD 9.00 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. The same quote showed a 52-week range of USD 3.94 to USD 12.64, volume of 362,371 shares and market capitalization of USD 1.2 billion, giving the stock a broad valuation range around the fiscal turnaround.